Shares of Catalent, Inc. (NYSE:CTLT – Get Free Report) have been given a consensus rating of “Hold” by the eight ratings firms that are presently covering the stock, MarketBeat reports. Eight ...

Catalent, Inc. CTLT reported first-quarter fiscal 2025 adjusted loss per share of 13 cents, flat year over year. The figure ...

Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

Catalent (CTLT) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of $0.11. This compares to loss of $0.10 per share a year ago. These figures are adjusted for ...

Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 ...

SOMERSET, N.J., October 21, 2024--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and ...

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Takeda Pharmaceutical Co. (TAK) and Catalent (CTLT). But which of these two stocks is more attractive ...

Roche's Q3 Sales Surge Led By Ocrevus, Vabysmo, Urges Regulators To Block Novo Holdings' $16.5B Catalent Acquisition Roche reported a 9% increase in third-quarter sales, driven by strong ...